Zostavax (shingles (herpes zoster) vaccine (live))
- Region
- 🇪🇺 EU
- Active substance
- shingles (herpes zoster) vaccine (live)
- Company
- Merck Sharp & Dohme B.V.
- Status
- Withdrawn
- Therapeutic area
- Herpes Zoster; Immunization
- CHMP opinion
- Thu 23 Mar 2006
- EU approval
- Fri 19 May 2006
- Application
- EMEA/H/C/000674
- ATC
- J07BK02
- Official record
- www.ema.europa.eu
Indication
Zostavax is indicated for prevention of herpes zoster ('zoster' or shingles) and herpes-zoster-related post-herpetic neuralgia. Zostavax is indicated for immunisation of individuals 50 years of age or older.
Regulatory milestones
No milestones recorded in the last year.
Follow Zostavax
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.